Hair loss in young men — brought into sharp focus by public interest in Lyle Menendez's hair and the toupee he reportedly wore during his 1990s murder trial — is far more common than many realise. Male pattern baldness can begin as early as the late teens, driven largely by genetic sensitivity to DHT, though stress, nutritional deficiencies, thyroid dysfunction, and autoimmune conditions can all play a role. Understanding the cause is essential before choosing a treatment. This article covers the signs, diagnosis, NHS-recognised treatments including minoxidil and finasteride, and when to seek medical advice about hair loss.

What Causes Hair Loss in Young Men?

Androgenetic alopecia, driven by DHT-induced follicular miniaturisation, is the most common cause, but telogen effluvium, alopecia areata, thyroid dysfunction, nutritional deficiencies, and medication side effects can all contribute.

Experiencing these side effects? Our pharmacists can help you navigate them →

Hair loss in young men is more common than many people realise, and it can begin as early as the late teens or early twenties. The causes are varied, and understanding the underlying mechanism is important for choosing the right approach to management.

The most prevalent cause is androgenetic alopecia, commonly known as male pattern baldness, which is driven by a genetic sensitivity to dihydrotestosterone (DHT) — a derivative of testosterone. DHT binds to receptors in hair follicles, causing them to miniaturise over time and eventually cease producing visible hair. This process can begin surprisingly early in genetically predisposed individuals.

Beyond genetics, several other factors can contribute to hair loss in younger men:

• Telogen effluvium — a temporary shedding triggered by physical or emotional stress, illness, nutritional deficiencies, or significant weight loss

• Alopecia areata — an autoimmune condition causing patchy hair loss, recognised by the NHS as distinct from pattern baldness

• Iron deficiency — assessed clinically using ferritin as the key marker; other nutritional deficiencies (such as zinc) may also play a role. Vitamin D deficiency has been associated with hair loss in some studies, though the evidence is largely associative; testing and treatment should only be considered if clinically indicated

• Thyroid dysfunction — both hypothyroidism and hyperthyroidism can disrupt the hair growth cycle

• Scalp conditions — such as tinea capitis (ringworm of the scalp, which is uncommon in adults but may occur in immunosuppressed individuals and typically requires systemic antifungal treatment) or seborrhoeic dermatitis

• Medication-induced hair loss — a number of commonly prescribed medicines can cause hair shedding, including retinoids, antiepileptics, anticoagulants, and beta-blockers; anabolic steroid use is also a recognised cause

• Traction alopecia and trichotillomania — hair loss resulting from prolonged mechanical tension on the hair or compulsive hair-pulling, respectively

• Scarring alopecias (e.g., lichen planopilaris, frontal fibrosing alopecia) — these are less common but important to recognise early, as follicular destruction is irreversible; prompt dermatology referral is essential if scarring alopecia is suspected

• Secondary syphilis — should be considered in cases of patchy, non-scarring hair loss where the clinical picture is atypical

Public interest in hair loss among young men has been heightened by high-profile cases in popular culture. For example, discussions around Lyle Menendez's hair — notably the toupee he reportedly wore during his widely televised trial in the 1990s — have prompted broader conversations about how hair loss affects young men's self-image and the coping strategies they adopt. Whilst there is no official clinical link between his specific circumstances and any medical cause, his case illustrates how hair loss can affect men from a very young age.

Not sure if this is normal? Chat with one of our pharmacists →

Sources: NHS Hair loss (alopecia); NICE CKS Hair loss assessment; PCDS Male pattern hair loss guidance; BAD patient information leaflets.

Male Pattern Baldness: Signs, Stages and Diagnosis

Male pattern baldness typically presents with bitemporal recession and vertex thinning, assessed using the Norwood-Hamilton Scale; diagnosis is clinical, with blood tests reserved for atypical or rapidly progressive presentations.

Male pattern baldness (androgenetic alopecia) follows a broadly predictable progression that clinicians assess using the Norwood-Hamilton Scale, a seven-stage classification system widely used in dermatology and trichology. Recognising the early signs allows for timely intervention, which is generally more effective than treatment initiated at advanced stages.

Early signs to look out for include:

• A receding hairline, typically beginning at the temples (bitemporal recession)

• Thinning at the crown (vertex) of the scalp

• Gradual reduction in hair density over the frontal and vertex regions

Note that diffuse or generalised shedding (hair on pillows, in the shower, or on hairbrushes) is more characteristic of telogen effluvium than of male pattern baldness, and the two conditions can coexist. A widening parting is more typical of female pattern hair loss.

Diagnosis is primarily clinical, based on the pattern and distribution of hair loss alongside a personal and family history. A GP or dermatologist may also perform trichoscopy (dermoscopy of the scalp) to assess follicular miniaturisation. Blood tests are not routinely required for classic androgenetic alopecia, but should be considered when the presentation is atypical, onset is rapid, hair loss is diffuse, or systemic symptoms are present. In such cases, tests may include thyroid function (TSH), full blood count, and ferritin. Broader hormonal panels should be reserved for cases where there are specific clinical indicators.

It is worth noting that male pattern baldness does not cause itching, scaling, or pain. If these symptoms are present alongside hair loss, an alternative or co-existing diagnosis — including scarring alopecia — should be considered and dermatology referral arranged promptly to prevent irreversible follicular loss.

UK clinical guidance (NICE CKS, PCDS) recommends that clinicians take a thorough history to differentiate androgenetic alopecia from other forms of alopecia before initiating treatment. Early-stage diagnosis is particularly valuable because treatments such as minoxidil and finasteride are most effective when hair follicles are still partially active rather than fully dormant.

Sources: NICE CKS Hair loss assessment; PCDS Male pattern hair loss; BAD Androgenetic alopecia patient information.

Hairpieces and Toupees: Psychological and Practical Considerations

Hairpieces are a non-pharmacological option for hair loss, but clip-based attachments can cause traction alopecia and occlusive adhesives may cause folliculitis; NHS funding is not available for male pattern baldness.

For men who are not candidates for medical treatment, or who prefer a non-pharmacological solution, hairpieces and toupees remain a widely used option. The subject gained notable public attention through the Lyle Menendez hair story — during his 1993–1994 murder trial, it was reported that Lyle wore a toupee, having experienced significant hair loss from a young age. This detail, whilst seemingly minor, sparked considerable public discussion about the psychological burden of early hair loss in young men and the lengths to which individuals may go to conceal it.

From a psychological standpoint, hair loss can have a meaningful impact on self-esteem, body image, and social confidence. Research in dermatology literature consistently identifies associations between androgenetic alopecia and increased rates of anxiety and depression, particularly in younger men for whom hair loss feels premature or unexpected. It is important that healthcare professionals approach this topic with sensitivity and without minimising the patient's concerns. Alopecia UK offers peer support and information for those affected.

Practical considerations for hairpieces include:

• Material — synthetic fibres are more affordable but less natural-looking; human hair pieces offer greater realism but require more maintenance

• Attachment method — options include adhesive tape, clips, or integration with existing hair; clip-based attachment can cause traction on surrounding follicles, and occlusive adhesives may occasionally cause folliculitis or contact dermatitis. Patch-testing adhesives before prolonged use is advisable for those with sensitive skin

• Maintenance — regular cleaning and professional fitting are important to avoid scalp irritation or infection

• Cost — quality hairpieces can be expensive. NHS provision of wigs and hairpieces is generally not available for male pattern baldness; however, funding may be available for hair loss resulting from medical causes (such as chemotherapy or alopecia areata), subject to local NHS policy

If scalp symptoms or signs of skin disease develop whilst using a hairpiece, seek advice from a GP or dermatologist rather than a trichologist alone. It should be noted that the title 'trichologist' is not statutorily regulated in the UK; if seeking specialist advice, look for practitioners affiliated with recognised professional bodies (such as the Institute of Trichologists or the Trichological Society), and involve a dermatologist if there is any concern about underlying scalp disease.

Sources: NHS Hair loss (alopecia); Alopecia UK; BAD patient information on wigs and camouflage.

NHS-Recognised Treatments for Male Hair Loss

Minoxidil (topical) and finasteride (1 mg oral, prescription-only) are the two NHS-recognised treatments for male pattern baldness; neither is a permanent cure and hair loss resumes if treatment stops.

The NHS recognises two principal pharmacological treatments for male pattern baldness: minoxidil and finasteride. Both have an established evidence base and are widely used in clinical practice, though it is important to understand that neither offers a permanent cure — hair loss typically resumes if treatment is discontinued.

Minoxidil is available over the counter as a topical solution (2% and 5%) or foam (5%). In line with UK SmPC guidance, the 5% foam and 5% solution for men are typically applied twice daily to the affected areas of the scalp. The precise mechanism of action is not fully understood, but minoxidil is thought to prolong the anagen (growth) phase of the hair cycle and improve blood flow to follicles. Common side effects include:

• Initial increased hair shedding in the first few weeks of use (this is temporary and does not indicate treatment failure)

• Scalp irritation or contact dermatitis — more common with solutions containing propylene glycol; the foam formulation may be better tolerated in sensitive individuals

• Rarely, unwanted facial hair growth

Results are typically seen after three to six months of consistent use. Always follow the directions in the product's patient information leaflet.

Finasteride (1 mg daily) is a prescription-only oral medication that works by inhibiting the enzyme 5-alpha reductase, thereby reducing DHT levels in the scalp by approximately 60–70%. Clinical trials demonstrate that finasteride stabilises hair loss in the majority of men and promotes regrowth in a significant proportion. Generic finasteride 1 mg tablets are widely available; prescribers should use the generic name rather than any brand name.

Important safety information — patients must be counselled on the following before starting treatment:

• Sexual side effects — including reduced libido, erectile dysfunction, and ejaculatory disorders. These are reported in a minority of users. The MHRA has issued guidance noting that persistent sexual dysfunction has been reported in some men even after stopping finasteride; patients should be made aware of this before commencing treatment

• Psychiatric effects — the MHRA has highlighted reports of depression and suicidal ideation in men taking finasteride. Patients should be advised to stop the medicine and seek medical advice promptly if they experience mood changes or low mood

• Male breast changes — gynaecomastia and breast tenderness have been reported rarely

• Patient alert card — in line with MHRA guidance, patients prescribed finasteride should be provided with the MHRA patient alert card, which summarises these risks

• Women of childbearing potential — finasteride is not indicated for use in women. Women who are pregnant or may become pregnant must not handle crushed or broken finasteride tablets due to the risk of absorption and potential harm to a male foetus

Suspected adverse reactions to finasteride or minoxidil should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

For men with more advanced hair loss, hair transplant surgery (follicular unit transplantation or follicular unit extraction) is available privately and can produce long-lasting, natural-looking results. The NHS does not routinely fund hair transplants for androgenetic alopecia. Anyone considering this procedure should choose a CQC-registered provider, ensure they receive a thorough pre-operative assessment, and be counselled on the risks, which include scarring, infection, and the possibility of suboptimal hair growth.

Sources: MHRA Drug Safety Update — finasteride: risk of psychiatric side effects and sexual dysfunction; emc SmPC: Finasteride 1 mg tablets; emc SmPC: Regaine for Men 5% Cutaneous Foam; NHS Hair loss treatment page.

When to Seek Medical Advice About Hair Loss

See a GP promptly if hair loss is sudden, patchy, accompanied by scalp inflammation, or associated with systemic symptoms, as these features may indicate a treatable or scarring cause requiring specialist assessment.

Whilst male pattern baldness is a benign condition, there are circumstances in which hair loss warrants prompt medical evaluation. Knowing when to consult a GP helps ensure that any underlying or treatable cause is identified without unnecessary delay.

You should contact your GP if you notice any of the following:

• Sudden or rapid hair loss over a short period

• Patchy hair loss rather than a diffuse or patterned thinning

• Hair loss accompanied by scalp redness, scaling, itching, pain, pustules, or perifollicular inflammation — these features may indicate a scarring alopecia or tinea capitis, both of which require prompt specialist assessment to prevent irreversible hair loss

• Hair loss alongside systemic symptoms such as fatigue, unexplained weight change, or symptoms suggestive of thyroid disease

• Signs of endocrine disturbance in men, such as gynaecomastia or sexual dysfunction, which may warrant further hormonal evaluation

• Hair loss following a significant illness, surgery, or period of extreme stress

• Hair loss in a child or adolescent

A GP will typically take a detailed history and, where clinically indicated, may arrange blood tests including thyroid function (TSH), full blood count, and ferritin. Broader hormonal panels should be requested only when there are specific clinical indicators, rather than routinely for all presentations of hair loss.

If a scarring alopecia is suspected — suggested by scalp inflammation, follicular plugging, perifollicular erythema, or tufting — prompt referral to a dermatologist is recommended, as follicular destruction in these conditions is irreversible and early treatment is essential. Tinea capitis, if suspected, requires systemic antifungal treatment and should not be managed with topical agents alone.

If an autoimmune cause such as alopecia areata is suspected, referral to a dermatologist may also be appropriate. NICE CKS and PCDS guidance supports a stepwise approach: exclude reversible causes first, then consider referral for specialist assessment or treatment if the diagnosis remains unclear or if first-line treatments have not been effective.

It is also worth seeking advice if hair loss is causing significant psychological distress. GPs can refer patients to talking therapies or support services where appropriate, and Alopecia UK offers peer support and information for those affected. Early, open conversations with a healthcare professional can make a meaningful difference — both in terms of clinical outcomes and emotional wellbeing. There is no need to manage hair loss in silence, and effective options are available for many men regardless of the stage or cause of their hair loss.

Sources: NICE CKS Hair loss assessment; PCDS Scarring alopecia overview; NHS Hair loss (alopecia) page; Alopecia UK.

Frequently Asked Questions